Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?

Obstetrics and Gynecology

Volumn 104, Issue 2, 2004, Pages 255-260

  Slomovitz, Brian M ^a   Sun, Charlotte C ^a   Ramirez, Pedro T ^a   Bodurka, Diane C ^a   Diaz, Paul ^a   Lu, Karen H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; BREAST CANCER; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG USE; ENDOMETRIUM CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; STATISTICAL SIGNIFICANCE; ADENOCARCINOMA; ARTICLE; BREAST TUMOR; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; MIDDLE AGED; MIXED MULLERIAN TUMOR; MORTALITY; REGISTER; RETROSPECTIVE STUDY; SURVIVAL; UNITED STATES;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MEDICAL RECORDS; MIDDLE AGED; MIXED TUMOR, MULLERIAN; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TEXAS;

EID: 4344612268     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000131620.67911.03     Document Type: Review

References (27)

1. Adami HO, Krusemo UB, Bergkvist L, Persson I, Pettersson B. On the age-dependent association between cancer of the breast and of the endometrium: a nationwide cohort study. Br J Cancer 1987;55:77-80.
2. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985;68:99-112.
3. Kazerouni N, Schairer C, Friedman HB, Lacey JV Jr, Greene MH. Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study. J Med Genet 2002;39:826-32.
4. Shapiro CL, Recht A. Side effects of adjuvant treatment of breast cancer. N Engl J Med 2001;344:1997-2008.
5. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:1-15.
6. Levine M, Moutquin JM, Walton R, Feightner J. Chemoprevention of breast cancer: a joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. CMAJ 2001;164:1681-90.
7. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237-8.
8. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
9. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000;356:881-7.
10. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
11. Barakat RR, Wong G, Curtin JP, Vlamis V, Hoskins WJ. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164-8.
12. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485-90.
13. Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 1994;13:248-58.
14. Wickerham DL, Fisher B, Wolmark N, Bryant J, Costantino J, Bernstein L, et al. Association of tamoxifen and uterine sarcoma. J Clin Oncol 2002;20:2758-60.
15. Curtis RE, Freedman DM, Sherman ME, Fraumeni JF Jr. Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 2004;96: 70-4.
16. American College of Obstetricians and Gynecologists. Tamoxifen and endometrial cancer. ACOG Committee Opinion 169. Washington, DC: AGOG; 1996.
17. Nasri MN, Coast GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333-8.
18. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447-51.
19. Gardner FJ, Konje JC, Brown L, Khanna S, Bell SC, Taylor DJ, et al. Uterine surveillance of asymptomatic postmenopausal women taking tamoxifen. Climacteric 1998;1:180-7.
20. Mourits MJ, Ten Hoor KA, van der Zee AG, Willemse PH, de Vries EG, Hollema H. The effects of tamoxifen on proliferation and steroid receptor expression in postmenopausal endometrium. J Clin Pathol 2002;55:514-9.
21. Mourits MJ, Hollema H, De Vries EG, Ten Hoor KA, Willemse PH, Van Der Zee AG. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol 2002;33: 341-6.
22. Hague S, Manek S, Oehler MK, MacKenzie IZ, Bicknell R, Rees MC. Tamoxifen induction of angiogenic factor expression in endometrium. Br J Cancer 2002;86:761-7.
23. Anzai Y, Holinka CF, Kuramoto H, Gurpide E. Stimulatory effects of 4-hydroxytamoxifen on proliferation of human endometrial adenocarcinoma cells (Ishikawa line). Cancer Res 1989;49:2362-5.
24. Barsalou A, Gao W, Anghel SI, Carriere J, Mader S. Estrogen response elements can mediate agonist activity of anti-estrogens in human endometrial Ishikawa cells. J Biol Chem 1998;273:17138-46.
25. Sakamoto T, Eguchi H, Omoto Y, Ayabe T, Mori H, Hayashi S. Estrogen receptor-mediated effects of tamoxifen on human endometrial cancer cells. Mol Cell Endocrinol 2002;192:93-104.
26. Ferguson SE, Olshen AB, Viale A, Awtrey CS, Barakat RR, Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol Oncol 2004;92: 719-25.
27. Wilder JL, Shajahan S, Khattar NH, Wilder DM, Yin J, Rushing RS, et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol 2004;92: 553-8.